Another Promising Neuroblastoma Discovery
(Source: American Cancer Society :: News and Features)
Source: American Cancer Society :: News and Features - September 1, 2016 Category: Cancer & Oncology Source Type: news
Loss of a microRNA family, let-7, found key in neuroblastoma
(Boston Children's Hospital) A study led by researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, finds that a microRNA called let-7 plays a central role in curbing neuroblastoma and could focus efforts to find a targeted, nontoxic alternative to chemotherapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 7, 2016 Category: Global & Universal Source Type: news
What Are The Most Common Pediatric Cancers?
Discussion
Cancer occurs in all ages including children. Fortunately cancer is much less common in the pediatric age group accounting for <1% of all cancers yearly in the US. Approximately 10,000 US children under age 15 will be diagnosed with cancer in 2016. More than 80% of those children will survive more than 5 years because of advances in direct cancer treatment and treatment of its complications. Survival rates depend on a number of factors including the type of cancer and location. Despite these good numbers, about 1250 children in the US die yearly from pediatric cancer. After accidents, childhood cancer, suicid...
Source: PediatricEducation.org - July 4, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Tandem myeloablative ASCT consolidation boosts neuroblastoma outcomes
Research presented at the American Society of Clinical Oncology annual conference suggests that consolidation therapy with tandem compared with single myeloablative autologous stem cell transplant can improve outcomes in paediatric patients with high-risk neuroblastoma. (Source: MedWire News)
Source: MedWire News - June 11, 2016 Category: Consumer Health News Tags: Oncology Source Type: news
Tandem beats single ASCT for childhood neuroblastoma
CHICAGO – More children treated for high-risk neuroblastoma who received a second autologous stem cell transplant in consolidation after induction chemotherapy were alive after 3 years compared with... (Source: Clinical Neurology News)
Source: Clinical Neurology News - June 9, 2016 Category: Neurology Source Type: news
Practice Changer: Tandem Transplant for Neuroblastoma
(MedPage Today) -- 13% absolute increase in 3-year event-free survival (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 9, 2016 Category: Hematology Source Type: news
IL-2 adds only toxicity to neuroblastoma antibody tx
CHICAGO – Adding the cytokine IL-2 to front-line therapy with the anti-GD2 antibody ch14.18/CHO provided no additional survival benefit and only added to toxicity in the treatment of pediatric... (Source: Clinical Neurology News)
Source: Clinical Neurology News - June 8, 2016 Category: Neurology Source Type: news
Double Stem Cell Transplant May Help Fight a Childhood Cancer
Tandem treatments might give survival edge to kids with neuroblastoma, researcher saysSource: HealthDay
Related MedlinePlus Pages: Cancer Chemotherapy, Neuroblastoma, Stem Cells (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - June 7, 2016 Category: Consumer Health News Source Type: news
Double Stem Cell Transplant May Help Fight a Childhood Cancer
Tandem treatments might give survival edge to kids with neuroblastoma, researcher says (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - June 7, 2016 Category: Cancer & Oncology Source Type: news
Double Stem Cell Transplant May Help Fight a Childhood Cancer
Tandem treatments might give survival edge to kids with neuroblastoma, researcher says (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 6, 2016 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Oncology, Pediatrics, Research, News, Source Type: news
Immunotherapy, chemotherapy combo effective in children with neuroblastoma
Stephen FellerANN ARBOR, Mich., June 6 (UPI) -- A combination of chemotherapy and immunotherapy shrank or eliminated tumors in more than half of children with recurrent cancer, according to a recent study. (Source: Health News - UPI.com)
Source: Health News - UPI.com - June 6, 2016 Category: Consumer Health News Source Type: news
Dual stem-cell transplant improves outlook for children with high-risk neuroblastoma
Children with high-risk neuroblastoma whose treatment included two autologous stem-cell transplants were more likely to be free of cancer three years later than patients who underwent a single transplant, a Phase 3 clinical trial has found. The tandem transplant technique produced even better results when followed by treatment with immunotherapy agents. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 6, 2016 Category: Science Source Type: news
High-risk Neuroblastoma: Intensified Therapy Ups SurvivalHigh-risk Neuroblastoma: Intensified Therapy Ups Survival
An intensified 'tandem' myeloablative autologous stem cell transplant regimen has improved survival so much that survivorship issues are now being discussed. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 6, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Doctors unleash new weapon to fight pediatric neuroblastoma
(University of Michigan Health System) After the first year of receiving the novel treatment combination, more than half of children with relapsed neuroblastoma saw either a complete or partial remission -- a 53 percent response rate compared to the typical 10 to 12 percent response rate. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 6, 2016 Category: Cancer & Oncology Source Type: news
Dual stem-cell transplant improves outlook for children with high-risk neuroblastoma
(Dana-Farber Cancer Institute) Children with high-risk neuroblastoma whose treatment included two autologous stem-cell transplants were more likely to be free of cancer three years later than patients who underwent a single transplant, a Phase 3 clinical trial has found, according to research presented at the annual meeting of the American Society of Clinical Oncology. The tandem transplant technique produced even better results when followed by treatment with immunotherapy agents. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 5, 2016 Category: Global & Universal Source Type: news
